Literature DB >> 24067086

Development of RNA aptamers targeting Ebola virus VP35.

Jennifer M Binning1, Tianjiao Wang, Priya Luthra, Reed S Shabman, Dominika M Borek, Gai Liu, Wei Xu, Daisy W Leung, Christopher F Basler, Gaya K Amarasinghe.   

Abstract

Viral protein 35 (VP35), encoded by filoviruses, is a multifunctional dsRNA binding protein that plays important roles in viral replication, innate immune evasion, and pathogenesis. The multifunctional nature of these proteins also presents opportunities to develop countermeasures that target distinct functional regions. However, functional validation and the establishment of therapeutic approaches toward such multifunctional proteins, particularly for nonenzymatic targets, are often challenging. Our previous work on filoviral VP35 proteins defined conserved basic residues located within its C-terminal dsRNA binding interferon (IFN) inhibitory domain (IID) as important for VP35 mediated IFN antagonism and viral polymerase cofactor functions. In the current study, we used a combination of structural and functional data to determine regions of Ebola virus (EBOV) VP35 (eVP35) to target for aptamer selection using SELEX. Select aptamers, representing, two distinct classes, were further characterized based on their interaction properties to eVP35 IID. These results revealed that these aptamers bind to distinct regions of eVP35 IID with high affinity (10-50 nM) and specificity. These aptamers can compete with dsRNA for binding to eVP35 and disrupt the eVP35-nucleoprotein (NP) interaction. Consistent with the ability to antagonize the eVP35-NP interaction, select aptamers can inhibit the function of the EBOV polymerase complex reconstituted by the expression of select viral proteins. Taken together, our results support the identification of two aptamers that bind filoviral VP35 proteins with high affinity and specificity and have the capacity to potentially function as filoviral VP35 protein inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067086      PMCID: PMC3909728          DOI: 10.1021/bi400704d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  66 in total

1.  Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure.

Authors:  D H Mathews; J Sabina; M Zuker; D H Turner
Journal:  J Mol Biol       Date:  1999-05-21       Impact factor: 5.469

2.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

3.  Refinement of macromolecular structures by the maximum-likelihood method.

Authors:  G N Murshudov; A A Vagin; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-05-01

4.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

5.  Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Authors:  J A Wilson; M Bray; R Bakken; M K Hart
Journal:  Virology       Date:  2001-08-01       Impact factor: 3.616

6.  Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.

Authors:  Takeshi Noda; Hiroshi Sagara; Emiko Suzuki; Ayato Takada; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 7.  Towards a vaccine against Ebola virus.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Expert Rev Vaccines       Date:  2003-12       Impact factor: 5.217

8.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States.

Authors:  Allison Groseth; Ute Ströher; Steven Theriault; Heinz Feldmann
Journal:  Virus Res       Date:  2002-08       Impact factor: 3.303

10.  The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein.

Authors:  Yue Huang; Ling Xu; Yongnian Sun; Gary J Nabel
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970

View more
  28 in total

1.  Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery.

Authors:  Jan Hoinka; Alexey Berezhnoy; Phuong Dao; Zuben E Sauna; Eli Gilboa; Teresa M Przytycka
Journal:  Nucleic Acids Res       Date:  2015-04-13       Impact factor: 16.971

2.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

Review 3.  Strategies in Ebola virus disease (EVD) diagnostics at the point of care.

Authors:  Chad T Coarsey; Nwadiuto Esiobu; Ramswamy Narayanan; Mirjana Pavlovic; Hadi Shafiee; Waseem Asghar
Journal:  Crit Rev Microbiol       Date:  2017-04-25       Impact factor: 7.624

4.  AptaCluster - A Method to Cluster HT-SELEX Aptamer Pools and Lessons from its Application.

Authors:  Jan Hoinka; Alexey Berezhnoy; Zuben E Sauna; Eli Gilboa; Teresa M Przytycka
Journal:  Res Comput Mol Biol       Date:  2014

Review 5.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

6.  AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments.

Authors:  Phuong Dao; Jan Hoinka; Mayumi Takahashi; Jiehua Zhou; Michelle Ho; Yijie Wang; Fabrizio Costa; John J Rossi; Rolf Backofen; John Burnett; Teresa M Przytycka
Journal:  Cell Syst       Date:  2016-07       Impact factor: 10.304

7.  Therapeutics for postexposure treatment of Ebola virus infection.

Authors:  Marina Jerebtsova; Sergei Nekhai
Journal:  Future Virol       Date:  2015-03       Impact factor: 1.831

8.  RaptRanker: in silico RNA aptamer selection from HT-SELEX experiment based on local sequence and structure information.

Authors:  Ryoga Ishida; Tatsuo Adachi; Aya Yokota; Hidehito Yoshihara; Kazuteru Aoki; Yoshikazu Nakamura; Michiaki Hamada
Journal:  Nucleic Acids Res       Date:  2020-08-20       Impact factor: 16.971

9.  Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Authors:  Jens H Kuhn; Kristian G Andersen; Yīmíng Bào; Sina Bavari; Stephan Becker; Richard S Bennett; Nicholas H Bergman; Olga Blinkova; Steven Bradfute; J Rodney Brister; Alexander Bukreyev; Kartik Chandran; Alexander A Chepurnov; Robert A Davey; Ralf G Dietzgen; Norman A Doggett; Olga Dolnik; John M Dye; Sven Enterlein; Paul W Fenimore; Pierre Formenty; Alexander N Freiberg; Robert F Garry; Nicole L Garza; Stephen K Gire; Jean-Paul Gonzalez; Anthony Griffiths; Christian T Happi; Lisa E Hensley; Andrew S Herbert; Michael C Hevey; Thomas Hoenen; Anna N Honko; Georgy M Ignatyev; Peter B Jahrling; Joshua C Johnson; Karl M Johnson; Jason Kindrachuk; Hans-Dieter Klenk; Gary Kobinger; Tadeusz J Kochel; Matthew G Lackemeyer; Daniel F Lackner; Eric M Leroy; Mark S Lever; Elke Mühlberger; Sergey V Netesov; Gene G Olinger; Sunday A Omilabu; Gustavo Palacios; Rekha G Panchal; Daniel J Park; Jean L Patterson; Janusz T Paweska; Clarence J Peters; James Pettitt; Louise Pitt; Sheli R Radoshitzky; Elena I Ryabchikova; Erica Ollmann Saphire; Pardis C Sabeti; Rachel Sealfon; Aleksandr M Shestopalov; Sophie J Smither; Nancy J Sullivan; Robert Swanepoel; Ayato Takada; Jonathan S Towner; Guido van der Groen; Viktor E Volchkov; Valentina A Volchkova; Victoria Wahl-Jensen; Travis K Warren; Kelly L Warfield; Manfred Weidmann; Stuart T Nichol
Journal:  Viruses       Date:  2014-09-26       Impact factor: 5.048

Review 10.  Aptamers in diagnostics and treatment of viral infections.

Authors:  Tomasz Wandtke; Joanna Woźniak; Piotr Kopiński
Journal:  Viruses       Date:  2015-02-16       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.